While public health officials and hospital representatives are portraying Hantavirus pulmonary syndrome as being unassailable, waiting for a vaccine to arrive, the story on favipiravir is being suppressed.
Favipiravir(6-fluoro-3-hydroxy-2-pyrazinecarboxamide), orT-705, represents a significant advancement in the development of broad-spectrum antiviral therapeutics. Unlike nucleoside analogs that mimic natural precursors,favipiravirfunctions as a potent, selective inhibitor of theviral RNA-dependent RNA polymerase (RdRp)complex.
Upon entering the cellular environment,T-705undergoes intracellular phosphoribosylation to its active form,favipiravir-ribofuranosyl-5’-triphosphate (T-705-RTP). This active metabolite acts as a pseudo-purine, effectively terminating viral RNA chain elongation. This mechanism is particularly effective against the negative-sense, single-stranded RNA viruses responsible forHantavirus Pulmonary Syndrome (HPS), includingAndes virus(ANDV) andSin Nombre virus(SNV).
Preclinical data have consistently demonstrated thatfavipiravirprovides substantial protection when administered in the early phases of infection. In the hamster model of HPS—which recapitulates the severe pulmonary edema and capillary leak syndrome observed in human patients—T-705significantly reduced mortality rates and viral titers in pulmonary and lymphatic tissues.
Crucially,favipiravirexhibits superior pharmacokinetic profiles compared toribavirin, the conventional, albeit problematic, standard of care for HPS.Ribavirinis characterized by significant hematological toxicity, including dose-dependent hemolytic anemia. In contrast,favipiraviris generally better tolerated, exhibiting a wider therapeutic window and fewer dose-limiting side effects in mammalian models, positioning it as the premier candidate for clinical translation.
Click here for an enlarged view
Safronetz D, Falzarano D, Scott DP, Furuta Y, Feldmann H, Gowen BB. Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrob Agents Chemother. 2013 Oct;57(10):4673-80. doi: 10.1128/AAC.00886-13. Epub 2013 Jul 15. PMID: 23856782; PMCID: PMC3811478.
The oral route is the well-established delivery method forfavipiravir. These tablets are typically manufactured as 200 mg immediate-release units for human use. Because the drug undergoes extensive metabolism by aldehyde oxidase (AO) and to a lesser extent by xanthine oxidase, it requires relatively high loading doses to achieve and maintain therapeutic plasma concentrations. In instances where patients are unable to swallow tablets—such as those in critical care settings—compounded oral suspensions administered via nasogastric tubes could be utilized.
The availability offavipiravirvaries significantly by jurisdiction, reflecting the complex interplay between public health crises and pharmaceutical regulation.
Favipiravirstands as a robust candidate for treating highly pathogenic hantaviral infections. While animal models confirm its high inhibitory potential and favorable safety profile compared toribavirin, human clinical data remain the missing link for definitive validation. Future clinical trials must prioritize optimized dosing regimens to maximize efficacy in the critical early window of HPS progression. The passengers in biocontainment facilities and in home quarantine should be urgently tested with oral favipiravir. Additionally, the thirty crew and medical personnel currently on the contaminated MV Hondius sailing for Rotterdam should have favipiravir airlifted to them on the ship.
Source: Global Research
